Tegal Receives Shareholder Approval to Change Corporate Name to CollabRx, Inc.

  Tegal Receives Shareholder Approval to Change Corporate Name to CollabRx,
  Inc.

Business Wire

SAN FRANCISCO -- September 25, 2012

Tegal Corporation (NASDAQ: TGAL) today announced shareholder approval of an
amendment to its Certificate of Incorporation changing its corporate name to
CollabRx, Inc. Tegal obtained shareholder approval of the name change at its
annual meeting today.

CollabRx stock will begin trading Thursday, September 27, 2012 on the Nasdaq
Stock Market under the symbol, CLRX. The corporate name and trading symbol
change follows the July 12, 2012, closing of a transaction in which Tegal
acquired CollabRx, Inc., a privately held technology company in the rapidly
growing market of interpretive content and data analytics for genomics-based
medicine.

The Chief Executive Officers of the two constituent companies, Thomas Mika of
Tegal and James Karis of CollabRx, serve as co-CEOs of the combined, publicly
traded company, with headquarters in San Francisco, CA. Mr. Mika continues to
be Chairman of the company.

Shareholders today approved the election of Messrs. Mika and Karis, as well as
Tegal directors Gilbert Bellini, Jeffrey M. Krauss and Carl Muscari, to
one-year terms as members of the CollabRx Board of Directors. Shareholders
today also ratified the appointment of Burr, Pilger & Mayer LLP as the
company’s Independent Registered Public Accounting Firm for the fiscal year
ending March 31, 2013.

The corporate name change will not affect the validity or transferability of
any currently outstanding stock certificates. It is not necessary for
shareholders with certified shares to surrender or exchange any stock
certificates they currently hold as a result of the corporate name change.

CollabRx offers cloud-based expert systems that provide clinically relevant
interpretive knowledge to institutions, physicians, researchers and patients
for genomics-based medicine in cancer and other diseases to inform health care
decision making. With access to approximately 50 clinical and scientific
advisors at leading academic institutions and a suite of tools and processes
that combine artificial intelligence-based analytics with proprietary
interpretive content, the company is well positioned to participate in the
$300 billion value-added “big data” opportunity in the US health care market
(as reported by McKinsey Global Institute), over half of which specifically
targets areas in cancer and cancer genomics.^1

CollabRx content is dynamically updated and organized in a knowledgebase that
includes information on molecular diagnostics, medical tests, clinical trials,
drugs, biologics and other information relevant for cancer treatment planning.
Capturing how highly respected practicing physicians use this information in
the clinical setting further refines the knowledgebase.

“The publicly traded CollabRx is a technology leader informing the next
generation of health care,” said Mr. Mika. “CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's top cancer
experts – and we are starting with the area of greatest need: advanced cancers
in patients who have effectively exhausted the standard of care. We gratified
that our shareholders, partners and clients are so supportive of our mission.”

CollabRx, Inc.

CollabRx is a recognized leader in “cloud-based” expert systems to inform
health care decision-making. CollabRx uses information technology to aggregate
and contextualize the world's knowledge on genomics-based medicine with
specific insights from the nation's top cancer experts starting with the area
of greatest need: advanced cancers in patients who have effectively exhausted
the standard of care. More information may be obtained at www.collabrx.com.

Safe Harbor Statement

This press release contains forward-looking statements that may include
statements regarding the intent, belief or current expectations of Tegal,
CollabRx and their respective management. Forward looking statements include
statements about the benefits and advantages of the acquisition for Tegal and
CollabRx. Actual results could differ materially from those projected in the
forward-looking statements as a result of a number of important factors,
including but not limited to the risk that the acquisition will not close as
the transaction is subject to certain closing conditions. In addition, if and
when the transaction is closed, there will be risks and uncertainties related
to Tegal’s ability to integrate CollabRx successfully, the risk that the
anticipated benefits from the acquisition may not be fully realized or may
take longer to realize than expected; and competition and its effect on the
combined company’s performance. Additional factors that may affect future
results are contained in the SEC filings for Tegal, including but not limited
to Tegal’s Annual Report on Form 10-K for the year ended March 31, 2012. Tegal
and CollabRx each disclaim any obligation to update and revise statements
contained in this release based on new information or otherwise.

^1 “Big data: The next frontier for innovation, competition and productivity”,
McKinsey Global Institute, May 2011

Contact:

Robert Ferri Partners, LLC
Robert Ferri, 415-575-1589 (direct)
robert.ferri@robertferri.com
 
Press spacebar to pause and continue. Press esc to stop.